Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

2.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

3.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators.

N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777.

4.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.

Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.

PMID:
22901886
5.

Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.

Liu Y, Zhang S, Li DW, Jiang SJ.

PLoS One. 2013;8(3):e59872. doi: 10.1371/journal.pone.0059872. Epub 2013 Mar 27. Erratum in: PLoS One. 2013;8(6). doi: 10.1371/annotation/8da4be4b-2de1-4c51-9c40-0f49dc212579.

6.

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R.

Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.

7.

Mepolizumab versus placebo for asthma.

Powell C, Milan SJ, Dwan K, Bax L, Walters N.

Cochrane Database Syst Rev. 2015 Jul 27;(7):CD010834. doi: 10.1002/14651858.CD010834.pub2. Review.

PMID:
26214266
8.

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group.

Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71. Epub 2007 Sep 13.

PMID:
17872493
9.

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.

Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.

Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558.

PMID:
19828470
10.

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators.

N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.

11.

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.

Hilvering B, Xue L, Pavord ID.

Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Epub 2015 Apr 21. Review.

PMID:
25900924
13.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.

Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.

PMID:
25306557
14.

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.

Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA.

Respir Res. 2013 Sep 19;14:93. doi: 10.1186/1465-9921-14-93.

15.

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E.

Lancet Respir Med. 2015 Sep;3(9):692-701. doi: 10.1016/S2213-2600(15)00197-6. Epub 2015 Jul 28.

PMID:
26231288
16.

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS.

Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. Epub 2002 Oct 17.

PMID:
12406833
17.

Mepolizumab and eosinophil-mediated disease.

Walsh GM.

Curr Med Chem. 2009;16(36):4774-8. Review.

PMID:
19929788
18.

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.

Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-131. doi: 10.1080/14737167.2017.1298444. Epub 2017 Mar 17.

PMID:
28277854
19.

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.

Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG.

Ann Am Thorac Soc. 2014 May;11(4):531-6. doi: 10.1513/AnnalsATS.201310-354OC.

PMID:
24606022
20.

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group.

Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18.

PMID:
21852542

Supplemental Content

Support Center